Foundayo, the GLP-1 Weight Loss Pill: What Women in Menopause Should Know

Foundayo (orforglipron) is a once-daily GLP-1 pill for weight management that the FDA approved in April 2026. Unlike the Wegovy pill, which has to be taken on an empty stomach, Foundayo can be taken with or without food. If you are in perimenopause or menopause, and especially if you already take hormone therapy, it raises practical questions the headlines skip: how much weight people lost in the trials, what the side effects are, and whether it changes how your other pills work.

This guide sticks to what the FDA-approved label and the trials behind it actually say, and it is clear about what they do not say.

What Foundayo is and who it is approved for

Foundayo contains orforglipron, a GLP-1 receptor agonist. It acts on the same receptor as semaglutide (Ozempic, Wegovy), and on one of the two receptors targeted by tirzepatide (Mounjaro, Zepbound), but it comes as a tablet instead of an injection.

Its label approves it, alongside a reduced-calorie diet and more physical activity, to reduce excess body weight and keep it off long term in adults with obesity, or in adults with overweight who also have at least one weight-related health condition. The label also says that using it together with another GLP-1 receptor agonist is not recommended.

How it is taken

• One tablet a day, with or without food, swallowed whole rather than broken, crushed or chewed.
• The dose starts at 0.8 mg and goes up no faster than every 30 days, through 2.5 mg and 5.5 mg, and then, depending on how you respond and how well you tolerate it, to 9 mg, 14.5 mg or 17.2 mg.
• The gradual increase is intended to reduce gastrointestinal side effects. In the trials, nausea, vomiting and diarrhea were more frequent while the dose was being increased and decreased over time.

What the trials found

The label reports two randomized, placebo-controlled trials that lasted 72 weeks. Everyone in them also received advice on diet and physical activity.

• Adults without diabetes: average weight loss of 7.4%, 8.3% and 11.1% at the 5.5 mg, 9 mg and 17.2 mg doses, against 2.1% with placebo. At the highest dose, 54.5% of people lost at least 10% of their body weight, against 13% with placebo.
• Adults with type 2 diabetes: average weight loss of 5.1%, 7.0% and 9.6% at the same doses, against 2.5% with placebo.

Two cautions before reading too much into those numbers. First, between 7% and 24% of the people in each trial group had no weight recorded at 72 weeks, and the label's figures fill those gaps with statistical estimates. Second, the trials included adults aged 18 to 88 in the trial without diabetes and 20 to 92 in the trial with type 2 diabetes, but the label does not report results by perimenopause or menopause status. Applying these overall averages specifically to women in menopause therefore requires extrapolation.

Foundayo and the Wegovy pill

Foundayo is not the only GLP-1 pill for weight management. The FDA approved Wegovy as a tablet (oral semaglutide) in December 2025. One practical difference is how each one is taken:

• Foundayo: once a day, with or without food.
• Wegovy tablets: once a day on an empty stomach in the morning with up to 4 ounces of water, then at least 30 minutes before eating, drinking, or taking other medicines by mouth.

That timing rule matters if your morning already includes other pills, such as oral hormone therapy or thyroid medicine. The weight-loss percentages for the two drugs come from different trials with different participants, so comparing them directly is not a fair test. If you are choosing between them, the routine that fits your day and your other medicines is a reasonable thing to weigh with your prescriber.

Can you take Foundayo with HRT?

Nothing in Foundayo's label lists menopausal hormone therapy as a combination to avoid. What the label does say:

• Foundayo slows stomach emptying, which may affect how other medicines taken by mouth are absorbed.
• Women using birth control pills are told to switch to a non-oral method, or add a barrier method, for 30 days after starting and for 30 days after each dose increase. The label notes that the effect on oral contraceptives has not been evaluated in a clinical trial, and that hormonal contraceptives not taken by mouth should not be affected.

That instruction is about contraception, not menopausal HRT, and a finding about birth control pills does not tell you what happens to oral estradiol or progesterone. The Foundayo label does not say whether its effect on stomach emptying changes how much oral estradiol or progesterone you absorb. If any part of your hormone therapy is taken by mouth, ask your prescriber whether your regimen should be reviewed when you start Foundayo or when the dose goes up. Our guide to taking a GLP-1 and HRT together covers what the other GLP-1 labels say.

If you are still having periods in perimenopause and could become pregnant, the birth-control instruction applies to you directly. The label advises effective contraception during treatment, says Foundayo may cause fetal harm, and says it should be stopped when a pregnancy is recognized.

Side effects and warnings

In the trials, the most common side effects were digestive: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, bloating, burping, reflux and gas. Headache, fatigue and hair loss were also common. Across the two trials, 8% of people taking Foundayo stopped permanently because of side effects, compared with 3% on placebo. The rates were 6% at 5.5 mg, 9% at 9 mg and 10% at 17.2 mg, and stomach and bowel side effects accounted for most of those stops.

The label's warnings include:

• A boxed warning about the possible risk of thyroid C-cell tumors. Orforglipron is not active in rats or mice and did not produce tumors in rodents. However, it is active at the human GLP-1 receptor, and it is not known whether Foundayo causes thyroid tumors, including medullary thyroid carcinoma, in people. Do not use it if you or a family member has had medullary thyroid carcinoma, or if you have multiple endocrine neoplasia syndrome type 2 (MEN 2). Tell your clinician about a lump in your neck, hoarseness that does not go away, trouble swallowing or trouble breathing.
• Pancreatitis.
• Severe stomach and bowel side effects. It is not recommended for people with severe gastroparesis.
• Kidney injury due to dehydration from nausea, vomiting or diarrhea.
• Low blood sugar. The risk is higher when Foundayo is used with insulin or with medicines that increase insulin release.
• Serious allergic reactions. A previous serious allergic reaction to orforglipron or to any ingredient in Foundayo means you should not take it.
• Gallbladder problems.
• Worsening diabetic eye disease (retinopathy) in people with type 2 diabetes. The label says patients with a history of diabetic retinopathy should be monitored.
• Inhaling stomach contents during procedures that use general anesthesia or deep sedation. Tell the team that you take Foundayo before any planned surgery or procedure.

Foundayo also interacts with some medicines that affect the liver enzyme CYP3A4, and the label limits simvastatin to 20 mg a day when the two are taken together, so give your prescriber a complete medication list.

What to raise if you are in perimenopause or menopause

• Body composition. The label says Foundayo reduced both fat mass and lean mass, with a greater loss of fat mass. Ask your clinician how to keep your strength and lean mass while you lose weight. Our page on GLP-1 side effects in menopause goes into more detail.
• Your other pills. List everything you take by mouth, including hormone therapy and thyroid medicine, because Foundayo may change how oral medicines are absorbed.
• Your symptoms. Foundayo is a weight-management medicine. It is not approved to treat menopause symptoms such as hot flashes or night sweats.

How to get Foundayo

Foundayo needs a prescription. Cost and insurance coverage vary by plan, so check with your insurer and pharmacy before you start. Some telehealth services prescribe it online after reviewing your health history. Hers, one of our partners, offers Foundayo through its weight-loss service. When we checked on September 10, 2026, Hers listed Foundayo medication starting at $149 a month if prescribed. It also required a separate Weight Loss Membership, priced at $39 for the first month and then $149 a month. Prices, eligibility and availability can change, so confirm the complete cost before enrolling.

If you are comparing options more broadly, our guides to getting Ozempic or Wegovy during menopause and Zepbound versus Wegovy for women cover the injectable choices, and our overview of GLP-1 medications in menopause explains how this class of medicine works.

The bottom line

Foundayo gives women another way to take a GLP-1 medicine, with no food timing to work around, and its label shows greater weight loss than placebo in adults over 72 weeks. It has not been studied specifically in menopause, and its label does not discuss menopausal hormone therapy. The label separately warns that slower stomach emptying may affect oral medicines, and it gives specific instructions for women using oral hormonal contraceptives. If you are considering it, bring your full medication list, including any hormone therapy, to that conversation.

Sources: the FDA-approved Foundayo prescribing information and Wegovy prescribing information, published by the National Library of Medicine on DailyMed; the FDA's Foundayo approval record and Wegovy tablet approval letter; and Hers's Foundayo page for pricing.